特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
594579

注目市場の分析:過敏性腸症候群 (IBS)

Market Spotlight: Irritable Bowel Syndrome (IBS)

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.35円
注目市場の分析:過敏性腸症候群 (IBS)
出版日: 2019年11月27日
発行: Datamonitor Healthcare
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、過敏性大腸症候群 (IBS) の治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法、規制環境と近年の主な出来事、現在開発中の治験の進行状況と上市スケジュール、主な治療薬の市場動向見通し (今後10年間分)、資本取引の動きなどを調査しております。

分析のポイント

疾患の背景事情

  • IBSの亜類型 (サブタイプ)

治療法

  • 緩下剤
  • 止瀉薬
  • 鎮痙薬
  • 抗うつ剤
  • セロトニン受容体作動薬
  • クロライドチャネル活性化剤
  • グアニル酸シクラーゼC作動薬
  • 抗生物質
  • オピオイド受容体
  • プロバイオティクス

疫学

上市済み医薬品

  • 各国での認証状況

パイプライン上の医薬品

間もなく生じる主な出来事

規制関連の主な出来事 (1件)

ライセンス契約・資産買収取引

母体特許

収益機会

治験情勢

  • スポンサー数:ステータス別
  • スポンサー数:フェーズ (相) 別

関連分析

  • 処方薬の情報

付録

目次
Product Code: DMKC0181355

This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 766 million prevalent cases of irritable bowel syndrome (IBS) in people aged 15 years and over worldwide, and forecasts that number to increase to 843 million prevalent cases by

2026. The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.

Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route.

The only high-impact upcoming event in the IBS space is the release of topline Phase II trial results for MD-7246. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 21.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.6 years in the overall gastroenterology (non inflammatory bowel disease) space.

There have been 20 licensing and asset acquisition deals involving IBS drugs during 2014-19. The $2,905m research, development, collaboration, and license agreement signed in 2017 between Allergan and Assembly Biosciences for the worldwide rights to Assembly's microbiome GI development programs was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 65% of trials in Phase I-II, and only 35% in Phase III-IV.

The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the IBS space is dominated by completed trials. Allergan and GlaxoSmithKline have the highest number of completed clinical trials for IBS, with 37 trials each.

Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

9 TREATMENT

9 Laxatives

9 Antidiarrheal drugs

9 Antispasmodics

9 Antidepressants

9 Serotonin receptor agonists

10 Chloride channel activators

10 Guanylyl cyclase C agonists

10 Antibiotics

10 Opioid receptors

10 Probiotics

12 EPIDEMIOLOGY

18 MARKETED DRUGS

21 PIPELINE DRUGS

27 RECENT EVENTS AND ANALYST OPINION

27 Zelnorm for IBS (July 8, 2019)

27 Multiple Drugs for IBS (June 25, 2019)

28 Linzess for IBS (June 18, 2019)

30 IB-Stim for IBS (June 7, 2019)

31 Zelnorm for IBS (October 17, 2018)

32 Zelnorm for IBS (October 15, 2018)

35 KEY UPCOMING EVENTS

36 KEY REGULATORY EVENTS

36 Ardelyx Touts Ibsrela's Novel Mechanism Of Action For IBS-C

36 FDA Approves The First Device To Treat Pain Caused By IBS

36 Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment

36 Zelnorm Returning To US Market With Broad IBS-C Indication

38 PROBABILITY OF SUCCESS

39 LICENSING AND ASSET ACQUISITION DEALS

39 AstraZeneca Acquires All Linzess Rights In China

39 Alfasigma Acquires Sloan's Zelnorm

40 Deals Shaping The Medical Industry, January 2019

41 PARENT PATENTS

42 REVENUE OPPORTUNITY

43 CLINICAL TRIAL LANDSCAPE

44 Sponsors by status

45 Sponsors by phase

47 BIBLIOGRAPHY

48 Prescription information

49 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Trends in prevalent cases of IBS, 2017-26
  • 17 Figure 2: Prevalent cases of IBS, by age group, 2017
  • 21 Figure 3: Overview of pipeline drugs for IBS in the US
  • 22 Figure 4: Pipeline drugs for IBS, by company
  • 22 Figure 5: Pipeline drugs for IBS, by drug type
  • 22 Figure 6: Pipeline drugs for IBS, by classification
  • 30 Figure 7: Linzess for IBS (June 18, 2019): Phase IIIb - IBS-C Abdominal Symptoms
  • 34 Figure 8: Zelnorm for IBS (October 15, 2018)
  • 35 Figure 9: Key upcoming events in IBS
  • 38 Figure 10: Probability of success in the IBS pipeline
  • 39 Figure 11: Licensing and asset acquisition deals in IBS, 2014-19
  • 41 Figure 12: Parent patents in IBS
  • 43 Figure 13: Clinical trials in IBS
  • 43 Figure 14: Top 10 drugs for clinical trials in IBS
  • 44 Figure 15: Top 10 companies for clinical trials in IBS
  • 44 Figure 16: Trial locations in IBS
  • 45 Figure 17: IBS trials status
  • 46 Figure 18: IBS trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Prevalent cases of IBS, 2017-26
  • 15 Table 2: Prevalent cases of IBS, by gender, 2017
  • 16 Table 3: Prevalence of IBS, by gender, 2017
  • 19 Table 4: Marketed drugs for IBS
  • 24 Table 5: Pipeline drugs for IBS in the US
  • 27 Table 6: Zelnorm for IBS (July 8, 2019)
  • 28 Table 7: Multiple Drugs for IBS (June 25, 2019)
  • 29 Table 8: Linzess for IBS (June 18, 2019)
  • 30 Table 9: IB-Stim for IBS (June 7, 2019)
  • 32 Table 10: Zelnorm for IBS (October 17, 2018)
  • 33 Table 11: Zelnorm for IBS (October 15, 2018)
  • 42 Table 12: Historical global sales, by drug ($m), 2014-18
  • 42 Table 13: Forecasted global sales, by drug ($m), 2019-23
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.